These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29847195)

  • 1. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
    Boboridis KG; Konstas AGP
    Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
    Levy O; Labbé A; Borderie V; Laroche L; Bouheraoua N
    J Fr Ophtalmol; 2016 Mar; 39(3):292-307. PubMed ID: 26997607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
    Yang JM; Choi W; Kim N; Yoon KC
    Optom Vis Sci; 2015 Sep; 92(9):e296-302. PubMed ID: 26107023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
    Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
    BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
    Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
    Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of inflammation in dry eye disease: Recommendations from a European panel of experts.
    Messmer EM; Ahmad S; Benitez Del Castillo JM; Mrukwa-Kominek E; Rolando M; Vitovska O; Baudouin C;
    Eur J Ophthalmol; 2023 May; 33(3):1294-1307. PubMed ID: 36471573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern possibilities of pathogenetically oriented therapy for dry eye syndrome].
    Brzheskiy VV
    Vestn Oftalmol; 2023; 139(2):95-103. PubMed ID: 37067938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease.
    Hind J; Macdonald E; Lockington D
    Eye (Lond); 2019 Apr; 33(4):685-686. PubMed ID: 30498263
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.